Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
National Centre of Competence in Research (NCCR) TransCure, University of Bern, Bern, Switzerland.
J Am Soc Nephrol. 2023 Jul 1;34(7):1179-1190. doi: 10.1681/ASN.0000000000000122. Epub 2023 Apr 17.
Thiazide diuretics (thiazides) are among the most widely prescribed drugs worldwide, but their use is associated with glucose intolerance and new-onset diabetes mellitus. The molecular mechanisms remain elusive. Our study reveals that thiazides attenuate insulin secretion through inhibition of the mitochondrial carbonic anhydrase isoform 5b (CA5b) in pancreatic β cells. We furthermore discovered that pancreatic β cells express only one functional carbonic anhydrase isoform, CA5b, which is critical in replenishing oxaloacetate in the mitochondrial tricarboxylic acid (TCA) cycle (anaplerosis). These findings explain the mechanism for thiazide-induced glucose intolerance and reveal a fundamental role of CA5b in TCA cycle anaplerosis and insulin secretion in β cells.
Thiazide diuretics are associated with glucose intolerance and new-onset diabetes mellitus. Previous studies demonstrated that thiazides attenuate insulin secretion, but the molecular mechanisms remain elusive. We hypothesized that thiazides attenuate insulin secretion via one of the known molecular thiazide targets in β cells.
We performed static insulin secretion experiments with islets of wild-type, Sodium/chloride co-transporter (NCC) (SLC12A3), and sodium-driven chloride/bicarbonate exchanger (NDCBE) (SLC4A8) knock-out (KO) mice and with murine Min6 cells with individual knockdown of carbonic anhydrase (CA) isoforms to identify the molecular target of thiazides in β cells. CA isoform 5b (CA5b) KO mice were then used to assess the role of the putative thiazide target CA5b in β -cell function and in mediating thiazide sensitivity in vitro and in vivo .
Thiazides inhibited glucose- and sulfonylurea-stimulated insulin secretion in islets and Min6 cells at pharmacologically relevant concentrations. Inhibition of insulin secretion by thiazides was CO 2 /HCO 3- -dependent, not additive to unselective CA inhibition with acetazolamide, and independent of extracellular potassium. By contrast, insulin secretion was unaltered in islets of mice lacking the known molecular thiazide targets NCC or NDCBE. CA expression profiling with subsequent knockdown of individual CA isoforms suggested mitochondrial CA5b as a molecular target. In support of these findings, thiazides significantly attenuated Krebs cycle anaplerosis through reduction of mitochondrial oxaloacetate synthesis. CA5b KO mice were resistant to thiazide-induced glucose intolerance, and thiazides did not alter insulin secretion in CA5b KO islets.
Thiazides attenuate insulin secretion via inhibition of the mitochondrial CA5b isoform in β cells of mice.
噻嗪类利尿剂(噻嗪类)是全球应用最广泛的药物之一,但它们的使用与葡萄糖耐量受损和新发糖尿病有关。其分子机制仍不清楚。我们的研究表明,噻嗪类通过抑制胰腺β细胞中的线粒体碳酸酐酶同工酶 5b(CA5b)来减弱胰岛素分泌。我们还发现,胰腺β细胞仅表达一种功能性碳酸酐酶同工酶 CA5b,它在补充线粒体三羧酸(TCA)循环(氨甲酰化作用)中的草酰乙酸中起关键作用。这些发现解释了噻嗪类药物引起的葡萄糖耐量受损的机制,并揭示了 CA5b 在 β 细胞的 TCA 循环氨甲酰化作用和胰岛素分泌中的基本作用。
噻嗪类利尿剂与葡萄糖耐量受损和新发糖尿病有关。先前的研究表明,噻嗪类药物减弱了胰岛素的分泌,但分子机制仍不清楚。我们假设噻嗪类药物通过β细胞中已知的分子噻嗪类靶标之一来减弱胰岛素的分泌。
我们使用野生型、钠/氯共转运体(SLC12A3)(NCC)和钠驱动的氯离子/碳酸氢盐交换器(SLC4A8)敲除(KO)小鼠的胰岛以及具有单个碳酸酐酶(CA)同工型敲低的鼠 Min6 细胞进行静态胰岛素分泌实验,以鉴定β细胞中噻嗪类的分子靶标。然后使用 CA 同工型 5b(CA5b)KO 小鼠来评估假定的噻嗪类靶标 CA5b 在β细胞功能中的作用,并在体外和体内介导噻嗪类药物的敏感性。
噻嗪类药物以药理学相关浓度抑制葡萄糖和磺酰脲刺激的胰岛素分泌。噻嗪类药物对胰岛素分泌的抑制作用是 CO 2 / HCO 3-依赖性的,与乙酰唑胺的非选择性 CA 抑制作用不叠加,并且与细胞外钾无关。相比之下,在缺乏已知分子噻嗪类靶标 NCC 或 NDCBE 的小鼠胰岛中,胰岛素分泌未改变。使用随后的单个 CA 同工型敲低进行 CA 表达谱分析表明,线粒体 CA5b 是一种分子靶标。这些发现的支持,噻嗪类药物通过减少线粒体草酰乙酸合成显着减弱三羧酸(TCA)循环氨甲酰化作用。CA5b KO 小鼠对噻嗪类诱导的葡萄糖耐量受损具有抗性,并且噻嗪类药物不会改变 CA5b KO 胰岛中的胰岛素分泌。
噻嗪类药物通过抑制小鼠β细胞中的线粒体 CA5b 同工型来减弱胰岛素分泌。